Investigators led by Wu and colleagues reported that STAiR18 therapy improved survival outcomes in multiple myeloma patients in a recent study. The data show a measurable survival benefit tied to the STAiR18 approach, which the authors presented as a potential new therapeutic avenue for a disease with evolving standards of care. The study details suggest STAiR18 may modulate disease biology to extend progression‑free and overall survival, but researchers stressed the need for confirmatory randomized trials to validate efficacy, characterize safety and determine how STAiR18 integrates with current regimens.